This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Teleflex to Introduce Arrow AC3 Optimus at EuroPCR, Paris
by Zacks Equity Research
Teleflex Inc. (TFX) announced plans to introduce Arrow AC3 Optimus Intra-Aortic Balloon Pump at the European Association for Percutaneous Cardiovascular Interventions Course (EuroPCR) in Paris during May 16--19.
Can Inogen (INGN) Stock Continue to Grow Earnings?
by Zacks Equity Research
Inogen, Inc (INGN) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
Inogen (INGN) Beats Earnings and Revenue Estimates in Q1
by Zacks Equity Research
Inogen (INGN) reported a stellar first quarter of 2017, beating the Zacks Consensus Estimate for both the counts. The company witnessed solid growth in revenues and adjusted earnings on a year-over-year basis.
Medical Product Q1 Earnings Due on May 9: XRAY, HSIC & More
by Zacks Equity Research
Medical product, an important part of the medical device subcategory within the broader Medical sector, looks promising at the moment.
Cardinal Health (CAH) Q3 Earnings Beat Estimates, Rise Y/Y
by Zacks Equity Research
Cardinal Health Inc. (CAH) reported third-quarter fiscal 2017 adjusted earnings of $1.53 per share, which beat the Zacks Consensus Estimate of $1.46 and increased 7% on a year-over-year basis.
Accuray (ARAY) Incurs Loss in Q3, Revenues Miss Estimates
by Zacks Equity Research
Accuray Inc.(ARAY) reported a loss of 6 cents per share in the third quarter of fiscal 2017, comparing unfavorably with the Zacks Consensus Estimate of earnings of a penny.
IDEXX Laboratories (IDXX) Beats Q1 Earnings, Raises View
by Zacks Equity Research
IDEXX Laboratories Inc. (IDXX) recorded first-quarter 2017 earnings per share (EPS) of 77 cents, up 51% (up 53% at constant exchange rate or CER) year over year on a reported basis.
ResMed (RMD) Beats Q3 Earnings, Misses Sales Estimates
by Zacks Equity Research
ResMed Inc. (RMD) announced third-quarter fiscal 2017 adjusted earnings per share (EPS) of 71 cents, up 2.8% from the prior-year quarter level.
Abaxis (ABAX) Beats Q4 Earnings Estimates, Revenues In Line
by Zacks Equity Research
Abaxis, Inc. (ABAX) reported fourth-quarter fiscal 2017 adjusted earnings per share of 33 cents, a penny ahead of the Zacks Consensus Estimate.
athenahealth (ATHN) Misses on Earnings & Revenues in Q1
by Zacks Equity Research
athenahealth Inc. (ATHN) reported adjusted earnings of 10 cents per share in the first quarter of fiscal 2017, which missed the Zacks Consensus Estimate by a penny.
Mead Johnson (MJN) Lags Q1 Earnings, Awaits Merger Closure
by Zacks Equity Research
Mead Johnson Nutrition Company (MJN) reported first-quarter 2017 adjusted earnings per share (EPS) of 80 cents at constant exchange rate or CER, down 8% year over year.
Zimmer Biomet (ZBH) Beats on Q1 Earnings, Lowers Guidance
by Zacks Equity Research
Zimmer Biomet Holdings, Inc. (ZBH) reported first-quarter 2017 adjusted earnings per share (EPS) of $2.13, up 6% year over year.
Boston Scientific (BSX) Misses on Q1 Earnings, Updates View
by Zacks Equity Research
Boston Scientific Corporation (BSX) posted adjusted EPS 29 cents in the first quarter, up 5.3% from the year-ago quarter.
Varian Medical (VAR) Beats on Earnings and Revenues in Q2
by Zacks Equity Research
Varian Medical Systems, Inc. (VAR) reported adjusted earnings of 89 cents per share in the second quarter of fiscal 2017, which beat the Zacks Consensus Estimate by a penny.
Pacific Biosciences (PACB) Q1 Loss Wider than Estimated
by Zacks Equity Research
Pacific Biosciences of California Inc. (PACB) reported a loss of 26 cents per share in the first quarter of 2017. The figure is 3 cents wider than the Zacks Consensus Estimate.
Integra LifeSciences (IART) Misses Q1 Earnings, Retains View
by Zacks Equity Research
Integra LifeSciences Holdings Corporation (IART) reported adjusted earnings per share of 39 cents in the first quarter of 2017, which marked a 2.6% increase from the year-ago number.
Thermo Fisher (TMO) Tops Q1 Earnings, Sales, Raises Guidance
by Zacks Equity Research
Thermo Fisher Scientific, Inc. (TMO) reported better-than-expected first-quarter 2017 earnings results.
Illumina (ILMN) Posts In-line Earnings in Q1, Margins Down
by Zacks Equity Research
Illumina Inc. (ILMN) reported adjusted earnings per share (EPS) of 64 cents in the first quarter of 2017
Edwards Lifesciences (EW) Tops Q1 Earnings, Updates '17 View
by Zacks Equity Research
Edwards Lifesciences Corp. (EW) reported first-quarter 2017 adjusted earnings per share (EPS) of 94 cents, which surpassed the Zacks Consensus Estimate by 14.6%.
Baxter International (BAX) Q1 Earnings Beat, FY17 View Up
by Zacks Equity Research
Baxter International Inc. (BAX) reported first-quarter 2017 adjusted earnings of 58 cents per share, which surpassed the Zacks Consensus Estimate by 7 cents and was way better than the year-ago figure of 36 cents.
NuVasive (NUVA) Beats on Q1 Earnings, Retains 2017 View
by Zacks Equity Research
NuVasive, Inc. (NUVA) reported first-quarter 2017 adjusted earnings per share (EPS) of 38 cents, reflecting an 18.7% rise from the year-ago quarter.
LabCorp (LH) Tops Q1 Earnings, Misses on Sales, Tweaks View
by Zacks Equity Research
Laboratory Corporation of America Holdings (LH) or LabCorp reported first-quarter 2017 adjusted earnings per share (EPS) of $2.22, up 8.3% from the year-ago quarter.
Express Scripts (ESRX) Earnings Top in Q1, FY17 View Up
by Zacks Equity Research
Express Scripts Holding Company (ESRX) posted first-quarter 2017 adjusted earnings per share of $1.33, beating the Zacks Consensus Estimate by a penny.
C.R. Bard (BCR) Beats Q1 Earnings & Revenues, FY17 View Up
by Zacks Equity Research
C.R. Bard Inc. (BCR) reported adjusted earnings of $2.87 in the first quarter of 2017, exceeding the Zacks Consensus Estimate of $2.65.
Baxter Launches Drug Library Guide for Smart Infusion System
by Zacks Equity Research
Baxter International Inc. (BAX) recently introduced an infusion system drug library guide to help clinicians identify potential errors in the infusion process during intravenous treatment.